Toronto-based Raymond James analysts Rahul Sarugaser and Michael Freeman say the strong cannabis stocks are beginning to separate from the weak. They pick two to buy.
Fundamentals are improving across the   Read More

A manufacturer of higher-value, higher-margin edible, vape and beverage products and a provider of incision-free therapies for the treatment of prostate cancer are “strong buys”.

Before this year’s stock market correction,   Read More

A manufacturer of higher-value, higher-margin edible, vape and beverage products and a provider of incision-free therapies for the treatment of prostate cancer are “strong buys”.

Before this year’s stock market correction,   Read More

Investor’s Digest of Canada contributors Doug Cooper and David Kideckel, Toronto-based Beacon Securities equity analysts, argue the United States is in the midst of a pot revolution. Americans are hankering   Read More